Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

EntreMed Files to Begin Clinical Trial of Cancer Drug in China

publication date: Jan 7, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
EntreMed, a Washington DC-area biotech, has filed an application with the SFDA to begin clinical trials in China of its cancer treatment, ENMD-2076. The trial is a US-China Phase II test of the drug in patients with triple-negative breast cancer. EntreMed said that adding a China arm to the trial would shorten the time necessary for patient recruitment and save on other costs as well. More details....

Stock Symbol: (NSDQ: ENMD)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...